Avacta Group is developing novel cancer immunotherapies and powerful diagnostics based on its two proprietary platforms - Affimer® biologics and pre|CISION™ tumour targeted chemotherapies.
|Admission date:||26 Jan 2016|
No Results & Reports data for this company
|25 Apr 2023||Investor Webinar|
|16 Apr 2023||Annual Meeting|
|23 Jun 2022||Annual General Meeting|